Pharmaceutical product recall and educated hesitancy towards new drugs and novel vaccines. By Peter Rhodes and Peter | Parry (11/06/24)
ED NOTE Thanks to Jeff Childers of Coffee & Covid — ☕️ JOE’S WAR ☙ Monday, December 23, 2024 ☙ C&C NEWS 🦠 — for highlighting this article! Childers wrote: The peer-reviewed study savaged the covid shots. While on its face broadly critical of the entire pharmaceutical safety process, the study cleverly situated the covid ‘vaccines’ within the broader history of botched pharmaceutical recalls and horrifying medical scandals. The authors drew parallels to other scandalous cases like Vioxx, Thalidomide, and the miscarriage drug DES. All the drugs were highly profitable, were marketed as “safe and effective,” eventually showed hair-raising long-term side effects, and for too many, the recalls occurred painfully slowly.
Study Summary:
Many pharmaceutical products have required recall from the marketplace due to adverse events. The authors systematic review found market recalls for 462 pharmaceutical products between 1953 and 2013. Today, while excess mortality figures are high in many countries, they receive limited attention and are often ignored or dismissed by mainstream news outlets. This excess mortality may include adverse effects from pharmaceutical agents that use gene-code technology.
The authors selectively reviewed historical pharmaceutical recalls and compared adverse issues from those drugs with recent COVID-19 vaccines. They found many parallels between past drug withdrawals and today’s gene-based vaccines, including:
Distortion of clinical trial data, with critical adverse event data absent from high-impact journal publications.
Delayed of regulatory action on pharmacovigilance data (e.g., VAERS) that should have triggered market withdrawal. Past examples: Vioxx (rofecoxib), Thalidomide, and Diethylstilbestrol (DES). Current example: Gene-based COVID-19 vaccines.
Conclusion:
“Public health requires access to raw clinical trial data, improved transparency from corporations, and heightened, active pharmacovigilance worldwide.”